🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Onvansertib

    Cardiff Oncology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  2. Onvansertib

    Cardiff Oncology

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  3. Onvansertib

    Cardiff Oncology

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  4. Onvansertib

    Cardiff Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  5. Opevesostat, -, CABAZITAXEL , -, FLUDROCORTISONE , Olaparib, HYDROCORTISONE , DEXAMETHASONE , -, -, -, -, Olaparib, DOCETAXEL , -

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  6. Organoid-guided treatment

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Orgovyx 120 mg film-coated tablets

    Fondazione Telethon ETS

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  8. Osimertinib + Savolitinib

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Oxaliplatin

    Universal Integrated

    Previously Treated Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Oxaliplatin

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. Oxaliplatin, 5FU, leucovorin

    Hospital Authority, Hong Kong

    Biliary Cancer Metastatic

    phase 2 small molecule active

    1 trial

  12. PACLITAXEL , BNT326, CARBOPLATIN , BNT327, PEMBROLIZUMAB , PEMETREXED

    BioNTech SE

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Erbitux 5 mg/mL solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion

    Ningbo Cancer Hospital

    Head and neck squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  14. PACLITAXEL ALBUMIN-BOUND, NIVOLUMAB, CISPLATIN

    Fondazione Telethon ETS

    Patients with non-metastatic muscle invasive bladder cancer

    phase 2 small molecule active

    1 trial

  15. PACLITAXEL ALBUMIN-BOUND, PACLITAXEL , DOCETAXEL , Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion., mRNA-4157, CARBOPLATIN

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  16. PACLITAXEL, Durvalumab_IJB, CARBOPLATIN, Oleclumab_IJB

    The George Institute

    Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

    phase 2 small molecule active

    1 trial

  17. PACLITAXEL, LIBTAYO 350 mg concentrate for solution for infusion., CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. PACLITAXEL, MaaT033, CISPLATIN, CARBOPLATIN, GEMCITABINE, PACLITAXEL, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, GEMCITABINE, PEMETREXED, BEVACIZUMAB, PACLITAXEL, DOCETAXEL, PEMETREXED, DOCETAXEL, BEVACIZUMAB, GEMCITABINE, CISPLATIN, VINORELBINE, PACLITAXEL, CARBOPLATIN, VINORELBINE, CARBOPLATIN, VINORELBINE, PEMETREXED, VINORELBINE, DOCETAXEL, GEMCITABINE, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, PEMETREXED, PEMETREXED, CISPLATIN, PEMETREXED, DOCETAXEL

    The George Institute

    Advanced non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  19. PALBOCICLIB, Zoladex 3,6 mg implante en jeringa precargada, AZD8421, PALBOCICLIB, AZD8421, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, Camizestrant, PALBOCICLIB, ABEMACICLIB, PALBOCICLIB, ABEMACICLIB, AZD8421, ABEMACICLIB

    AstraZeneca AB

    Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

    phase 2 small molecule active

    1 trial

  20. PARP inhibitor 2X-121

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  21. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Breast Cancer

    phase 2 small molecule active

    1 trial

  22. PD 0332991

    Pfizer

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  23. PD-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer Patients

    phase 2 small molecule active

    1 trial

  24. PD-1 antibody Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancers

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources